180 related articles for article (PubMed ID: 27547772)
1. Compromised fidelity of B-cell tolerance checkpoints in AChR and MuSK myasthenia gravis.
Lee JY; Stathopoulos P; Gupta S; Bannock JM; Barohn RJ; Cotzomi E; Dimachkie MM; Jacobson L; Lee CS; Morbach H; Querol L; Shan JL; Vander Heiden JA; Waters P; Vincent A; Nowak RJ; O'Connor KC
Ann Clin Transl Neurol; 2016 Jun; 3(6):443-54. PubMed ID: 27547772
[TBL] [Abstract][Full Text] [Related]
2. Dysregulation of B Cell Repertoire Formation in Myasthenia Gravis Patients Revealed through Deep Sequencing.
Vander Heiden JA; Stathopoulos P; Zhou JQ; Chen L; Gilbert TJ; Bolen CR; Barohn RJ; Dimachkie MM; Ciafaloni E; Broering TJ; Vigneault F; Nowak RJ; Kleinstein SH; O'Connor KC
J Immunol; 2017 Feb; 198(4):1460-1473. PubMed ID: 28087666
[TBL] [Abstract][Full Text] [Related]
3. Autoreactive T and B cells in nervous system diseases.
Sun JB
Acta Neurol Scand Suppl; 1993; 142():1-56. PubMed ID: 8382894
[TBL] [Abstract][Full Text] [Related]
4. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies.
Hoch W; McConville J; Helms S; Newsom-Davis J; Melms A; Vincent A
Nat Med; 2001 Mar; 7(3):365-8. PubMed ID: 11231638
[TBL] [Abstract][Full Text] [Related]
5. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction.
Cole RN; Reddel SW; Gervásio OL; Phillips WD
Ann Neurol; 2008 Jun; 63(6):782-9. PubMed ID: 18384168
[TBL] [Abstract][Full Text] [Related]
6. Passive and active immunization models of MuSK-Ab positive myasthenia: electrophysiological evidence for pre and postsynaptic defects.
Viegas S; Jacobson L; Waters P; Cossins J; Jacob S; Leite MI; Webster R; Vincent A
Exp Neurol; 2012 Apr; 234(2):506-12. PubMed ID: 22326541
[TBL] [Abstract][Full Text] [Related]
7. Enrichment of serum IgG4 in MuSK myasthenia gravis patients.
Vergoossen DLE; Ruiter AM; Keene KR; Niks EH; Tannemaat MR; Strijbos E; Lipka AF; van der Zijde ECJ; van Tol MJD; Bakker JA; Wevers BA; Westerberg E; Borges LS; Tong OC; Richman DP; Illa I; Punga AR; Evoli A; van der Maarel SM; Verschuuren JJ; Huijbers MG
J Neuroimmunol; 2022 Dec; 373():577978. PubMed ID: 36240543
[TBL] [Abstract][Full Text] [Related]
8. Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction.
Gomez AM; Van Den Broeck J; Vrolix K; Janssen SP; Lemmens MA; Van Der Esch E; Duimel H; Frederik P; Molenaar PC; Martínez-Martínez P; De Baets MH; Losen M
Autoimmunity; 2010 Aug; 43(5-6):353-70. PubMed ID: 20380584
[TBL] [Abstract][Full Text] [Related]
9. MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis.
Farrugia ME; Robson MD; Clover L; Anslow P; Newsom-Davis J; Kennett R; Hilton-Jones D; Matthews PM; Vincent A
Brain; 2006 Jun; 129(Pt 6):1481-92. PubMed ID: 16672291
[TBL] [Abstract][Full Text] [Related]
10. [Myasthenia gravis with anti-acetylcholine receptor antibody or anti-muscle specific kinase antibody].
Konishi T
Brain Nerve; 2011 Jul; 63(7):695-704. PubMed ID: 21747139
[TBL] [Abstract][Full Text] [Related]
11. [Pathogenic mechanisms of myasthenia gravis induced by antibodies against muscle-specific kinase].
Maruyama N; Shigemoto K
Rinsho Shinkeigaku; 2007 Nov; 47(11):842-4. PubMed ID: 18210813
[TBL] [Abstract][Full Text] [Related]
12. Myasthenia gravis experimentally induced with muscle-specific kinase.
Shigemoto K; Kubo S; Jie C; Hato N; Abe Y; Ueda N; Kobayashi N; Kameda K; Mominoki K; Miyazawa A; Ishigami A; Matsuda S; Maruyama N
Ann N Y Acad Sci; 2008; 1132():93-8. PubMed ID: 18096854
[TBL] [Abstract][Full Text] [Related]
13. Anti-MuSK- and anti-AChR-positive myasthenia gravis induced by d-penicillamine.
Poulas K; Koutsouraki E; Kordas G; Kokla A; Tzartos SJ
J Neuroimmunol; 2012 Sep; 250(1-2):94-8. PubMed ID: 22683336
[TBL] [Abstract][Full Text] [Related]
14. Pathogenesis of myasthenia gravis: update on disease types, models, and mechanisms.
Phillips WD; Vincent A
F1000Res; 2016; 5():. PubMed ID: 27408701
[TBL] [Abstract][Full Text] [Related]
15. [Antibodies in myasthenia gravis].
Eymard B
Rev Neurol (Paris); 2009 Feb; 165(2):137-43. PubMed ID: 19162288
[TBL] [Abstract][Full Text] [Related]
16. Myopathy, muscle atrophy and tongue lipid composition in MuSK myasthenia gravis.
Nikolić AV; Bačić GG; Daković MŽ; Lavrnić SĐ; Rakočević Stojanović VM; Basta IZ; Lavrnić DV
Acta Neurol Belg; 2015 Sep; 115(3):361-5. PubMed ID: 25253293
[TBL] [Abstract][Full Text] [Related]
17. Suppression of experimental myasthenia gravis by a B-cell epitope-free recombinant acetylcholine receptor.
Yi HJ; Chae CS; So JS; Tzartos SJ; Souroujon MC; Fuchs S; Im SH
Mol Immunol; 2008 Nov; 46(1):192-201. PubMed ID: 18799218
[TBL] [Abstract][Full Text] [Related]
18. Epidemiological and immunological profile of muscle-specific kinase myasthenia gravis in Greece.
Tsiamalos P; Kordas G; Kokla A; Poulas K; Tzartos SJ
Eur J Neurol; 2009 Aug; 16(8):925-30. PubMed ID: 19374661
[TBL] [Abstract][Full Text] [Related]
19. A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis.
Zisimopoulou P; Evangelakou P; Tzartos J; Lazaridis K; Zouvelou V; Mantegazza R; Antozzi C; Andreetta F; Evoli A; Deymeer F; Saruhan-Direskeneli G; Durmus H; Brenner T; Vaknin A; Berrih-Aknin S; Frenkian Cuvelier M; Stojkovic T; DeBaets M; Losen M; Martinez-Martinez P; Kleopa KA; Zamba-Papanicolaou E; Kyriakides T; Kostera-Pruszczyk A; Szczudlik P; Szyluk B; Lavrnic D; Basta I; Peric S; Tallaksen C; Maniaol A; Tzartos SJ
J Autoimmun; 2014 Aug; 52():139-45. PubMed ID: 24373505
[TBL] [Abstract][Full Text] [Related]
20. AChR-myasthenia gravis switching to double-seropositive several years after the onset.
Zouvelou V; Zisimopoulou P; Psimenou E; Matsigkou E; Stamboulis E; Tzartos SJ
J Neuroimmunol; 2014 Feb; 267(1-2):111-2. PubMed ID: 24388224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
